Crestone

Executive Summary

Crestone, Inc. is a clinical-stage biopharmaceutical company headquartered in Boulder, Colorado, dedicated to developing novel small-molecule therapies for serious bacterial infections. Its lead candidate, CRS3123, is a first-in-class antibiotic targeting Clostridioides difficile infection (CDI) with a novel mechanism of action that spares the gut microbiome. The drug has successfully completed Phase 1 studies and is currently advancing in Phase 2 trials. Crestone's pipeline also includes preclinical programs addressing antibiotic-resistant Gram-positive infections and tuberculosis, positioning the company to address significant unmet medical needs in the infectious disease space. As a private company, Crestone is poised for potential value inflection upon clinical data readouts and strategic partnerships.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 topline data for CRS3123 in CDI60% success
• Q3 2026Financing round or grant announcement70% success
• Q4 2026Partnership or licensing deal for tuberculosis program30% success